Title |
The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
|
---|---|
Published in |
BMJ Open, October 2013
|
DOI | 10.1136/bmjopen-2013-003834 |
Pubmed ID | |
Authors |
Signe Foghsgaard, Louise Vedtofte, Elisabeth R Mathiesen, Jens A Svare, Lise L Gluud, Jens J Holst, Peter Damm, Filip K Knop, Tina Vilsbøll |
Abstract |
Pregnancy is associated with decreased insulin sensitivity, which is usually overcome by a compensatory increase in insulin secretion. Some pregnant women are not able to increase their insulin secretion sufficiently, and consequently develop gestational diabetes mellitus (GDM). The disease normally disappears after delivery. Nevertheless, women with previous GDM have a high risk of developing type 2 diabetes (T2D) later in life. We aim to investigate the early development of T2D in women with previous GDM and to evaluate whether treatment with the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, may modify their risk of developing T2D. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 1% |
Unknown | 85 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 16 | 19% |
Student > Bachelor | 12 | 14% |
Researcher | 10 | 12% |
Student > Ph. D. Student | 8 | 9% |
Student > Doctoral Student | 4 | 5% |
Other | 15 | 17% |
Unknown | 21 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 35% |
Nursing and Health Professions | 6 | 7% |
Social Sciences | 4 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Psychology | 3 | 3% |
Other | 13 | 15% |
Unknown | 26 | 30% |